Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

(2010) Jiahuai Tan et al.   Journal of Hematology & Oncology

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

(2009) M. Gupta et al.   BLOOD

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery

(2008) E. S. Jaffe et al.   BLOOD

High‐dose chemotherapy and immunotherapy in adult Burkitt lymphoma

(2008) Albert Oriol et al.   CANCER

Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma

(2008) Yuko Nomura et al.   CANCER SCIENCE

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

(2008) Mark S. Cragg et al.   JOURNAL OF CLINICAL INVESTIGATION

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway

(2008) W Zhang et al.   LEUKEMIA

A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children's Oncology Group

(2008) Timothy C. Griffin et al.   PEDIATRIC BLOOD & CANCER

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

(2008) A. J. Frew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA